SCHEMBL1300913

SCHEMBL1300913

CCOC(=O)c1cc(O)c(OC)cc1Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.55
DPP4 P27487 1/20 0.50
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 2/20 0.45
GAA P10253 1/20 0.45
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 1/20 0.44
NR1H2 P55055 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22208862 0.89 LCK (0.61) HSD17B2DPP4CA12CA1CA2
SCHEMBL27455432 0.85 HSD17B2 (0.59) HSD17B2DPP4CA12CA1CA2
SCHEMBL22208578 0.85 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL6859316 0.84 KMT2A (0.54) HSD17B2DPP4LCKFYNLMNA
SCHEMBL13468453 0.84 HSD17B2 (0.62) HSD17B2DPP4CA12CA1CA2
SCHEMBL24379203 0.83 LCK (0.53) CA12CA1CA2CA7CA9
SCHEMBL1301113 0.83 LCK (0.48) HSD17B2DPP4CA12CA1CA2
SCHEMBL13469249 0.83 HSD17B2 (0.56) HSD17B2DPP4CA12CA1CA2
SCHEMBL12109024 0.82 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL28097982 0.81 HSD17B2 (0.55) HSD17B2DPP4CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179087-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS Immunophage Biotech (Shanghai) Co., Ltd. (CN) 2025-06-05 US disclosed
CN-119403800-A Compounds and their use as LPAR5 antagonists 艾美斐生物医药科技(上海)有限公司 2025-02-07 CN disclosed
EP-4486742-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS IMMUNOPHAGE BIOTECH (SHANGHAI) CO., LTD. (CN) 2025-01-08 EP disclosed
WO-2023165591-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) 2023-09-07 WO disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
EP-2231665-A2 NOVEL COMPOSITIONS AND METHODS OF USE Ardea Biosciences, Inc. (US) 2010-09-29 EP disclosed
WO-2009089263-A2 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP HSD17B2 1203/4885DPP4 1648/4885CA12 4642/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP HSD17B2 1203/4885DPP4 1648/4885CA12 4642/4885
US-20250179087-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS LPAR5, LPAR3, LPAR2 HSD17B2 2314/4885DPP4 814/4885CA12 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.